Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

antibody

antibody is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 111
News articles 0
Drug details — antibody
Class
—
Route
—
Patents
20
Programs
111
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

antibody is an FDA-listed pharmaceutical active ingredient.

Key facts

INN antibody

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. 299AR301 Phase 3 · Biogen · Kidney Transplant Recipients with Late Antibody-Mediated Rej
  2. ALXN2220-ATTRCM-301 Phase 3 · Alexion Europe SAS · Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
  3. APHP211057 Phase 3 · PARItec · myelin oligodendrocytes glycoprotein antibody associated dis
  4. ARGX-113-2308 Phase 3 · Argenx · Acetylcholine Receptor Binding Antibody Seronegative General
  5. Anti-PD-1 antibody drug named Serplulimab Phase 3 · Chinese Academy of · Locally Advanced Rectal Cancer (LARC)
  6. Cinryze® Phase 3 · Takeda · Acute Antibody-Mediated Rejection (AMR)
  7. Clazakizumab Phase 3 · CSL Behring · Antibody-mediated Rejection
  8. Combined use of TPO-RAs with low-dose anti-CD20 antibody Phase 3 · Chinese Academy of · Immune Thrombocytopenia (ITP)

Related patents

Browse patents

  1. US 20260144884

    ANTI-LRRC15 ANTIBODY DRUG CONJUGATES

    Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 20260116972

    CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY

    Expires Wed Apr 25 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 20260115307

    ANTI-FUCOSYL-GM1 ANTIBODY DRUG CONJUGATES

    Expires Wed Apr 25 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. AU 2024342196

    NOVEL ECTEINASCIDIN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF

    Expires Wed Mar 28 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. AU 2024276234

    METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES

    Expires Wed Nov 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 2025325692

    METHODS OF TREATMENT USING ANTI-SEZ6 ANTIBODY DRUG CONJUGATES

    Expires Wed Oct 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12427201

    Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12415843

    Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12410249

    Low dose antibody-based methods for treating hematologic malignancies

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12384853

    Anti-HER2/PD1 bispecific antibody

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12371503

    Methods of treatment using a leptin receptor agonist antibody

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12357703

    Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12343394

    CD38 modulating antibody agents

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12344665

    Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12337199

    Stable antibody formulation

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12331107

    Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. TW 202523278

    Antibody drug conjugate platforms

    Expires Sun Jun 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12319729

    Anti-Staphylococcus aureus specific antibody and nucleic acid encoding sequence thereof, and uses of the same

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12319744

    Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is antibody?

antibody is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.